4DMedical Limited Stock

Equities

4DX

AU0000095416

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 02:10:44 2024-04-26 am EDT 5-day change 1st Jan Change
0.605 AUD +0.83% Intraday chart for 4DMedical Limited -0.82% -15.38%
Sales 2024 * 5.47M 3.57M Sales 2025 * 21.39M 13.98M Capitalization 235M 153M
Net income 2024 * -30M -19.6M Net income 2025 * -22M -14.37M EV / Sales 2024 * 36.7 x
Net cash position 2024 * 34.05M 22.25M Net cash position 2025 * 17.16M 11.21M EV / Sales 2025 * 10.2 x
P/E ratio 2024 *
-7.83 x
P/E ratio 2025 *
-10.6 x
Employees 131
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.38%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on 4DMedical Limited

1 day+0.83%
1 week-0.82%
Current month-6.92%
1 month-1.63%
3 months-2.42%
6 months+28.72%
Current year-15.38%
More quotes
1 week
0.60
Extreme 0.595
0.63
1 month
0.57
Extreme 0.565
0.66
Current year
0.53
Extreme 0.53
0.83
1 year
0.45
Extreme 0.45
1.27
3 years
0.29
Extreme 0.29
1.73
5 years
0.29
Extreme 0.29
2.98
10 years
0.29
Extreme 0.29
2.98
More quotes
Managers TitleAgeSince
Chief Executive Officer - 12-11-30
Director of Finance/CFO - 22-07-24
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member - -
Director/Board Member - 17-08-31
Director/Board Member 60 23-09-24
More insiders
Date Price Change Volume
24-04-26 0.605 +0.83% 352 556
24-04-24 0.6 -1.64% 160,544
24-04-23 0.61 +0.83% 273,207
24-04-22 0.605 -0.82% 130,806
24-04-19 0.61 +1.67% 451,246

Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT

More quotes
4DMedical Limited is an Australia-based medical technology company. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. It initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The Company provides its lung imaging technology to other selected clinics across the I-MED network.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6 AUD
Average target price
1.133 AUD
Spread / Average Target
+88.89%
Consensus

Quarterly revenue - Rate of surprise